Cost-effectiveness of overactive bladder treatments: from the US payer perspective.
Murray B, Hessami SH, Gultyaev D, Lister J, Dmochowski R, Gillard KK, Stanisic S, Tung A, Boer R, Kaplan S.
Murray B, et al. Among authors: gillard kk.
J Comp Eff Res. 2019 Jan;8(1):61-71. doi: 10.2217/cer-2018-0079. Epub 2018 Dec 4.
J Comp Eff Res. 2019.
PMID: 30511584
Free article.